Ultragenyx to Present at Upcoming Investor Conferences
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced virtual presentations at investor conferences. CFO Shalini Sharp will present at the Jefferies Healthcare Conference on June 3, 2020, at 2 PM ET, followed by CEO Emil D. Kakkis at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020, at 3:50 PM ET. Live and archived webcasts will be available on the company's website for 90 days post-event. Ultragenyx is focused on developing novel treatments for rare genetic diseases, aiming for efficient drug development to meet high unmet medical needs.
- None.
- None.
NOVATO, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will hold virtual presentations at the following upcoming investor conferences:
- Shalini Sharp, the company's Chief Financial Officer, will hold a virtual presentation at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2 PM ET.
- Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will hold a virtual presentation at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 3:50 PM ET.
The live and archived webcast of these presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Replays of the webcasts will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
FAQ
When is Ultragenyx's presentation at the Jefferies Healthcare Conference?
What is the date and time for Ultragenyx's presentation at the Goldman Sachs Conference?
Where can I find the webcasts of Ultragenyx's investor presentations?
What type of diseases does Ultragenyx focus on?
Who is leading Ultragenyx's management team?
